SystImmune, Inc. has received FDA approval for the IND application of BL-M17D1 targeting advanced solid tumors.

Nammi Therapeutics, Inc. has reported the first patient has received QXL138AM in a Phase 1 trial focused on advanced solid tumors and multiple myeloma.

Pheast Shares Latest Preclinical Findings on PHST001, an Anti-CD24 Checkpoint Inhibitor for Macrophages, at SITC 2024.

Radella Pharmaceuticals reveals preliminary results from the Phase 1a trial of MD-18, a groundbreaking peptide aimed at PTP1B to combat obesity.

TEZSPIRE achieved its two main goals in the Phase III WAYPOINT study involving patients with chronic rhinosinusitis and nasal polyps.

Palleon Pharmaceuticals shares findings from the Phase 1/2 GLIMMER-01 study on E-602 combined with Cemiplimab for solid tumor patients at the SITC Annual Meeting.

NextCure presents preclinical findings for LNCB74 and new clinical biomarker results for the NC410 combination at the Society for Immunotherapy of Cancer Annual Meeting.

Dupixent has been authorized in the EU as the first and sole treatment for young children suffering from eosinophilic esophagitis.

Hanmi Introduces New Obesity Treatment ‘HM17321’: A Breakthrough in Addressing Muscle Loss Linked to GLP-1.

Minghui Pharmaceutical Reports Positive Early Findings from Phase I Trial of MHB039A, a New Bispecific Antibody Targeting PD-1 and VEGF.

Arcus Biosciences reports that the combination of Domvanalimab and Zimberelimab enhanced overall survival in the ARC-10 trial involving patients with high PD-L1 NSCLC.

OSE Immunotherapeutics reports noteworthy and statistically significant findings from the Phase 2 trial of Lusvertikimab, an anti-IL7R monoclonal antibody.